Los Angeles, CA. February
10, 2020 - US Nuclear Corp. (OTC: UCLE) recently signed a stock purchase agreement
with start-up Grapheton Inc. to acquire a 40% stake in the company.
Similar to Elon Musk’s ‘Neuralink’, Grapheton is developing and
manufacturing an advanced new generation of wearable and implantable
brain-machine interface devices.
Grapheton’s long-term goal is dedicated specifically to treating
injuries and disease such as spinal injuries, pain reduction, Parkinson’s
Disease, epilepsy, stroke, and possibly Alzheimer’s. Grapheton already has several pivotal and
patented advantages in the field, including:
- . Grapheton’s
electrodes utilize a new carbon-based material that doesn’t corrode and can
last as long as 40 years or more compared to less than five years from other
providers, which is extremely important considering the invasive surgery
required for installation or maintenance of the probes.
- Self-charging
supercapacitor which uses the brain’s own salty liquid environment as the power
source, meaning that unlike other providers, no battery maintenance is required
to reinstall a new battery while also ensuring that aging batteries will not
leak any chemicals into the brain. Again,
a huge advantage for reducing the surgery and maintenance required.
- Two-way
electrical and chemical communication with brain neurons, meaning that
Grapheton’s probes can not only send electrical signals, but also listen,
record, and respond to the body’s electrical and chemical signals
simultaneously.
Grapheton’s products are already in use at various research
centers and currently include: ECoG probes (electrocorticography- monitoring
the electrical activity of the brain), spinal stimulation probes for spinal
injuries, brain chemical sensors, surface electrodes for MRIs, and other
micro-electrode arrays and electrochemical sensors. US Nuclear will provide systems engineering,
manufacturing, and marketing support to help Grapheton leverage their unique patented
advantages and make these products commercially available to all people who can
benefit from them. US Nuclear’s monetary
support will also enable Grapheton to research and develop new and exciting
brain-machine interface products.
Safe Harbor Act
This press release includes "forward-looking
statements" within the meaning of the safe harbor provisions of the United
States Private Securities Litigation Reform Act of 1995. Actual results may
differ from expectations, estimates and projections and, consequently, you
should not rely on these forward looking statements as predictions of future
events. Words such as "expect," "estimate,"
"project," "budget," "forecast,"
"anticipate," "intend," "plan," "may,"
"will," "could," "should," "believes,"
"predicts," "potential," "continue," and similar
expressions are intended to identify such forward-looking statements. These
forward-looking statements involve significant risks and uncertainties that
could cause the actual results to differ materially from the expected results.
Investors may find additional information regarding US
Nuclear Corp. at the SEC website at http://www.sec.gov, or the company’s website
at www.usnuclearcorp.com
CONTACT:
US Nuclear Corp. (OTCBB: UCLE)
Robert I. Goldstein, President, CEO, and
Chairman
Rachel Boulds, Chief Financial Officer
(818) 883 7043
Email: info@usnuclearcorp.com
Comments
Post a Comment